Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 4, 2001, Pages 606-617

  Willette, Robert N ^a,b   Anderson, Karen M ^a   Nelson, Allen H ^a   Olzinski, Alan R ^a   Woods, Tina ^a   Coatney, Robert W ^a   Aiyar, Nambi ^a   Ohlstein, Eliot H ^a   Barone, Frank C ^a  

^a GLAXOSMITHKLINE   (United States)

^b GlaxoSmith Kline ^*  (United States)

Author keywords

Cardiac performance; Endothelin; Endothelin A receptors; Endothelin B receptors; Enrasentan; Heart failure; Hypertension; Hypertrophy; Survival; Ventricular remodeling

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART INDEX; HEART PERFORMANCE; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; LIPID DIET; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARBOXYLIC ACIDS; HEART RATE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INDANS; MALE; MYOCARDIUM; PROTEIN PRECURSORS; RATS; RATS, INBRED SHR; RECEPTORS, ENDOTHELIN; SURVIVAL RATE; VENTRICULAR REMODELING;

EID: 0034834639     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200110000-00013     Document Type: Article

References (67)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Regulation of endothelin-1 production by a thromboxane A2 mimetic in rat heart smooth muscle cells
3. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function
4. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin-II-induced hypertrophy in cultured rat cardiomyocytes
5. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: A possible endogenous endothelin-1-mediated mechanism
6. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro
7. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy
8. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression
9. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells
10. Endothelin: New discoveries and rapid progress in the clinic
11. Cardiorenal actions of endothelin. I. Effects of converting enzyme inhibition
12. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells
13. Effects of endothelin-1 on renal function in humans; implications for physiology and pathophysiology
14. Growth regulatory properties of endothelins
15. Molecular pharmacology-endothelin versatility
16. Endothelin ET (A) receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload
17. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension
18. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes: A paracrine mechanism for myocardial cell hypertrophy
19. Endothelin stimulates degradation of phospholipids in isolated rat hearts
20. Cytotoxic effect of endothelin-1 during 'stimulated' ischemia in cultured myocytes
21. Myocardial endothelin: Does it play a role in heart failure?
22. Endothelin is a positive inotropic agent in human and rat heart in vitro
23. Plasma endothelin and pulmonary pressures in patients with congestive heart failure
24. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
25. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy
26. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
27. Plasma endothelin in chronic heart failure
28. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
29. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
30. Increased plasma concentrations of endothelin in chronic heart failure in humans
31. Elevated endothelin-1 in heart failure and loss of normal response to postural change
32. Endothelin in human congestive heart failure
33. Endothelin in chronic heart failure: Current position and future prospects
34. Salivary endothelin concentrations in the assessment of chronic heart failure
35. Plasma endothelin determination as a prognostic indicator or 1-year mortality after acute myocardial infarction
36. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
37. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure
38. Role of endothelin in the exercise intolerance of chronic heart failure
39. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
40. Circulating and myocardial endothelin is activated prior to the renin-angiotensin-aldosterone system during the transition to overt congestive heart failure
41. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
42. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium
43. Endothelin receptors in the failing and nonfailing human heart
44. Which endothelin receptors are functionally important in chronic heart failure?
45. Nonpeptide endothelin receptor antagonists. VI. Pharmacological characterization of SB217242, a potent and highly bioavailable endothelin receptor antagonist
46. Establishment of the stroke-prone spontaneously hypertensive rat (SHR)
47. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats
48. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling
49. Serial echocardiographic Doppler assessment of left ventricular geometry and function in rats with pressure overload hypertrophy; chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure
50. Echocardiographic characterization of left ventricular adaptation in a genetically determined heart failure rat model
51. Genetic predis-position to stroke in spontaneously hypertensive rats
52. Hemodynamics and metabolism in stroke-prone spontaneously hypertensive rats before manifestation of brain infarcts
53. Antihypertensive drugs in the stroke-prone spontaneously hypertensive rat
54. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
55. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and protein-uria in stroke-prone hypertensive rats
56. Vital epidemiologic clues in heart failure
57. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide
58. In vivo hemodynamic and inotropic effects of the endothelin agonist, IRL 1620
59. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators
60. Effects of bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure
61. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
62. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits
63. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction
64. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats
65. Therapy with the nonpeptide endothelin antagonist 97-139 in a murine model of congested heart failure: Reduction of cardiac mass and myofiber hypertrophy
66. Effects of endothelins on collagen turnover in cardiac fibroblasts
67. Distribution and functional significance of the endothelin receptor sub-types in the rat adrenal gland